HFE mutations and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 10, Issue 2-3, 2006, Pages 267-276

  Connor, James R ^a   Lee, Sang Y ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN; MUTANT PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CAUCASIAN; CELL LEVEL; CYTOLOGY; DEGENERATIVE DISEASE; GENE MUTATION; HEMOCHROMATOSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; MUTATIONAL ANALYSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 33751104718     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-102-311     Document Type: Review

References (100)

1. R.S. Ajioka and J.P. Kushner, Clinical consequences of iron overload in hemochromatosis homozygotes, Blood 101 (2003), 3351-3353; discussion 3354-3358.
2. M. Arredondo, P. Munoz, C.V. Mura and M.T. Nunez, HFE inhibits apical iron uptake by intestinal epithelial (Caco-2) cells, FASEB J 15 (2001), 1276-1278.
3. E. Barry, T. Derhammer and S.H. Elsea, Prevalence of three hereditary hemochromatosis mutant alleles in the michigan Caucasian population, Community Genet 8 (2005), 173-179.
4. G. Bartzokis, J.L. Cummings, D. Sultzer, V.W. Henderson, K.H. Nuechterlein and J. Mintz, White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study, Arch Neurol 60 (2003), 393-398.
5. G. Becker and D. Berg, Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound, Mov Disord 16 (2001), 23-32.
6. D. Berg, U. Hoggenmuller, E. Hofmann, R. Fischer, M. Kraus, M. Scheurlen and G. Becker, The basal ganglia in haemochromatosis, Neuroradiology 42 (2000), 9-13.
7. D. Berlin, G. Chong, H. Chertkow, H. Bergman, N.A. Phillips and H.M. Schipper, Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI, Neurobiol Aging 25 (2004), 465-474.
8. E. Beutler, V. Felitti, T. Gelbart and N. Ho, Genetics of iron storage and hemochromatosis, Drug Metab Dispos 29 (2001), 495-499.
9. E. Beutler, V.J. Felitti, J.A. Koziol, N.J. Ho and T. Gelbart, Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA, Lancet 359 (2002), 211-218.
10. S. Bodovitz, M.T. Falduto, D.E. Frail and W.L. Klein, Iron levels modulate alpha-secretase cleavage of amyloid precursor protein, J Neurochem 64 (1995), 307-315.
11. H.L. Bonkovsky, M. Poh-Fitzpatrick, N. Pimstone, J. Obando, A. Di Bisceglie, C. Tattrie, K. Tortorelli, P. LeClair, M.G. Mercurio and R.W. Lambrecht, Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America, Hepatology 27 (1998), 1661-1669.
12. Z.J. Bulaj, R.S. Ajioka, J.D. Phillips, B.A. LaSalle, L.B. Jorde, L.M. Griffen, C.Q. Edwards and J.P. Kushner, Disease-related conditions in relatives of patients with hemochromatosis, N Engl J Med 343 (2000), 1529-1535.
13. J.R. Burdo, D.A. Antonetti, E.B. Wolpert and J.R. Connor, Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system, Neuroscience 121 (2003), 883-890.
14. M.J. Burt, P.M. George, J.D. Upton, J.A. Collett, C.M. Frampton, T.M. Chapman, T.A. Walmsley and B.A. Chapman, The significance of haemochromatosis gene mutations in the general population: implications for screening, Gut 43 (1998), 830-836.
15. A.I. Bush, Metal complexing agents as therapies for Alzheimer's disease, Neurobiol Aging 23 (2002), 1031-1038.
16. V. Byrnes, E. Ryan, S. Barrett, P. Kenny, P. Mayne and J. Crowe, Genetic hemochromatosis, a Celtic disease: is it now time for population screening? Genet Test 5 (2001), 127-130.
17. G. Cairo, S. Recalcati, A. Pietrangelo and G. Minotti, The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage, Free Radic Biol Med 32 (2002), 1237-1243.
18. J. Cammermeyer, Deposition of iron in the paraventricular areas of the human brain in hemochromatosis, J Neuropathol Exp Nerol 6 (1947), 111-127.
19. G. Candore, F. Licastro, M. Chiappelli, C. Franceschi, D. Lio, C. Rita Balistreri, G. Piazza, G. Colonna-Romano, L.M. Grimaldi and C. Caruso, Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy, Mech Ageing Dev 124 (2003), 525-528.
20. H. Carlson, A.S. Zhang, W.H. Fleming and C.A. Enns, The hereditary hemochromatosis protein, HFE, lowers intracellular iron levels independently of transferrin receptor 1 in TRVb cells, Blood 105 (2005), 2564-2570.
21. P. Cheepsunthorn, M. Mangan, L. Radov, J. Reid and J.R. Connor, Characterization of a novel rat brain-derived microglia: Gene expression profiling, Society for Neuroscience 30th Annual Meeting abstract 26 (2001), 791.4.
22. P. Cheepsunthorn, L. Radov, S. Menzies, J. Reid and J.R. Connor, Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain, Glia 35 (2001), 53-62.
23. O. Combarros, M. Garcia-Roman, A. Fontalba, J.L. Fernandez-Luna, J. Llorca, J. Infante and J. Berciano, Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease, Dement Geriatr Cogn Disord 15 (2003), 151-154.
24. J.R. Connor, Metals and Oxidative Damage in Neurological Disorders, Plenum Press, New York, 1997.
25. J.R. Connor, E.A. Milward, S. Moalem, M. Sampietro, P. Boyer, M.E. Percy, C. Vergani, R.J. Scott and M. Chorney, Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimers Dis 3 (2001), 471-477.
26. J.R. Connor, B.S. Snyder, J.L. Beard, R.E. Fine and E.J. Mufson, Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease, J Neurosci Res 31 (1992), 327-335.
27. J.R. Connor, X.S. Wang, S.M. Patton, S.L. Menzies, J.C. Troncoso, C.J. Earley and R.P. Allen, Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome, Neurology 62 (2004), 1563-1567.
28. A.R. Curtis, C. Fey, C.M. Morris, L.A. Bindoff, P.G. Ince, P.F. Chinnery, A. Coulthard, M.J. Jackson, A.P. Jackson, D.P. McHale, D. Hay, W.A. Barker, A.F. Markham, D. Bates, A. Curtis and J. Burn, Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease, Nat Genet 28 (2001), 350-354.
29. C. Datz, T. Haas, H. Rinner, F. Sandhofer, W. Patsch and B. Paulweber, Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 44 (1998), 2429-2432.
30. M.C. Dekker, P.C. Giesbergen, O.T. Njajou, J.C. Van Swieten, A. Hofman, M.M. Breteler and C.M. Van Duijn, Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism, Neurosci Lett 348 (2003), 117-119.
31. C.Q. Edwards, L.M. Griffen and J.P. Kushner, The morbidity of hemochromatosis among clinically unselected homozygotes: preliminary report, Adv Exp Med Biol 356 (1994), 303-308.
32. P. Eikelenboom and W.A. van Gool, Neuroinflammatory perspectives on the two faces of Alzheimer's disease, J Neural Transm 111 (2004), 281-294.
33. J.N. Feder, A. Gnirke, W. Thomas, Z. Tsuchihashi, D.A. Ruddy, A. Basava, F. Dormishian, R. Domingo, M.C. Jr., Ellis, A. Fullan, L.M. Hinton, N.L. Jones, B.E. Kimmel, G.S. Kronmal, P. Lauer, V.K. Lee, D.B. Loeb, F.A. Mapa, E. McClelland, N.C. Meyer, G.A. Mintier, N. Moeller, T. Moore, E. Morikang, C.E. Prass, L. Quintana, S.M. Starnes, R.C. Schatzman, K.J. Brunke, D.T. Drayna, N.J. Risch, B.R. Bacon and R.K. Wolff, A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis, Nat Genet 13 (1996), 399-408.
34. J.N. Feder, D.M. Penny, A. Irrinki, V.K. Lee, J.A. Lebron, N. Watson, Z. Tsuchihashi, E. Sigal, P.J. Bjorkman and R.C. Schatzman, The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding, Proc Natl Acad Sci USA 95 (1998), 1472-1477.
35. J.N. Feder, Z. Tsuchihashi, A. Irrinki, V.K. Lee, F.A. Mapa, E. Morikang, C.E. Prass, S.M. Starnes, R.K. Wolff, S. Parkkila, W.S. Sly and R.C. Schatzman, The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression, J Biol Chem 272 (1997), 14025-14028.
36. G.P. Feeney and M. Worwood, The effects of wild-type and mutant HFE expression upon cellular iron uptake in transfected human embryonic kidney cells, Biochim Biophys Acta 1538 (2001), 242-251.
37. V.J. Felitti and E. Beutler, New developments in hereditary hemochromatosis, Am J Med Sci 318 (1999), 257-268.
38. P. Fergelot, M. Orhant, A. Thenie, P. Loyer, M. Ropert-Bouchet, S. Lohyer, J.Y. Le Gall and J. Mosser, Overexpression of wild-type and mutant HFE in a human melanocytic cell line reveals an intracellular bridge between MHC class I pathway and transferrin iron uptake, Biol Cell 95 (2003), 243-255.
39. R.E. Fleming, M.C. Migas, C.C. Holden, A. Waheed, R.S. Britton, S. Tomatsu, B.R. Bacon and W.S. Sly, Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis, Proc Natl Acad Sci USA 97 (2000), 2214-2219.
40. C.B. Gable, Hemochromatosis and dietary iron supplementation: implications from US mortality, morbidity, and health survey data, J Am Diet Assoc 92 (1992), 208-212.
41. F. Gleeson, E. Ryan, S. Barrett and J. Crowe, Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening, Eur J Gastroenterol Hepatol 16 (2004), 859-863.
42. E.F. Goodall, M.J. Greenway, I. van Marion, C.B. Carroll, O. Hardiman and K.E. Morrison, Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS, Neurology 65 (2005), 934-937.
43. N. Gordon, Friedreich's ataxia and iron metabolism, Brain Dev 22 (2000), 465-468.
44. C. Grabill, A.C. Silva, S.S. Smith, A.P. Koretsky and T.A. Rouault, MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knock-out mice, Brain Res 971 (2003), 95-106.
45. C.N. Gross, A. Irrinki, J.N. Feder and C.A. Enns, Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation, J Biol Chem 273 (1998), 22068-22074.
46. J.R. Gruen, V.L. Goei, K.M. Summers, A. Capossela, L. Powell, J. Halliday, H. Zoghbi, H. Shukla and S.M. Weissman, Physical and genetic mapping of the telomeric major histocompatibility complex region in man and relevance to the primary hemochromatosis gene (HFE), Genomics 14 (1992), 232-240.
47. X. Huang, M.P. Cuajungco, C.S. Atwood, R.D. Moir, R.E. Tanzi and A.I. Bush, Alzheimer's disease, beta-amyloid protein and zinc, J Nutr 130 (2000), 1488S-1492S.
48. R.I. Hussain, C.G. Ballard, J.A. Edwardson and C.M. Morris, Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans, Neurosci Lett 317 (2002), 13-16.
49. C.R. Jack, T.M. Jr., Wengenack, D.A. Reyes, M. Garwood, G.L. Curran, B.J. Borowski, J. Lin, G.M. Preboske, S.S. Holasek, G. Adriany and J.F. Poduslo, In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice, J Neurosci 25 (2005), 10041-10048.
50. H.A. Jackson, K. Carter, C. Darke, M.G. Guttridge, D. Ravine, R.D. Hutton, J.A. Napier and M. Worwood, HFE mutations, iron deficiency and overload in 10,500 blood donors, Br J Haematol 114 (2001), 474-484.
51. G.P. Jeffrey, K. Basclain, J. Hajek, S. Chakrabarti and P.C. Adams, Alternate splicing produces a soluble form of the hereditary hemochromatosis protein HFE, Blood Cells Mol Dis 25 (1999), 61-67.
52. M.D. Kirkitadze and A. Kowalska, Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease, Acta Biochim Pol 52 (2005), 417-423.
53. M. Kruszewski, Labile iron pool: the main determinant of cellular response to oxidative stress, Mutat Res 531 (2003), 81-92.
54. E. Lauret, M. Rodriguez, S. Gonzalez, A. Linares, A. Lopez-Vazquez, J. Martinez-Borra, L. Rodrigo and C. Lopez-Larrea, HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma, Am J Gastroenterol 97 (2002), 1016-1021.
55. J.A. Lebron, M.J. Bennett, D.E. Vaughn, A.J. Chirino, P.M. Snow, G.A. Mintier, J.N. Feder and P.J. Bjorkman, Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor, Cell 93 (1998), 111-123.
56. J.A. Lebron and P.J. Bjorkman, The transferrin receptor binding site on HFE, the class I MHC-related protein mutated in hereditary hemochromatosis, J Mol Biol 289 (1999), 1109-1118.
57. J.A. Lebron, A.P. West Jr. and P.J. Bjorkman, The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor, J Mol Biol 294 (1999), 239-245.
58. S.Y. Lee and J.R. Connor, Regulation of Hfe by stress factors in BV-2 cells, Neurobiol Aging 26 (2005), 803-812.
59. J.K. Limdi and J.R. Crampton, Hereditary haemochromatosis, Qjm 97 (2004), 315-324.
60. A. Lleo, R. Blesa, C. Angelopoulos, P. Pastor-Rubio, M. Villa, R. Oliva and E. Bufill, Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease, J Neurol Neurosurg Psychiatry 72 (2002), 820-821.
61. G. Lucotte and G. Mercier, Celtic origin of the C282Y mutation of hemochromatosis, Genet Test 4 (2000), 163-169.
62. M.T. Malecki, T. Klupa, M. Walus, W. Czogala, P. Greenlaw and J. Sieradzki, A search for association between hereditary hemochromatosis HFE gene mutations and type 2 diabetes mellitus in a Polish population, Med Sci Monit 9 (2003), BR91-95.
63. C.J. Maynard, R. Cappai, I. Volitakis, R.A. Cherny, A.R. White, K. Beyreuther, C.L. Masters, A.I. Bush and Q.X. Li, Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron, J Biol Chem 277 (2002), 44670-44676.
64. B. Mercier, C. Mura and C. Ferec, Putting a hold on HLA-H, Nat Genet 15 (1997), 234.
65. A.T. Merryweather-Clarke, J.J. Pointon, A.M. Jouanolle, J. Rochette and K.J. Robson, Geography of HFE C282Y and H63D mutations, Genet Test 4 (2000), 183-198.
66. S. Moalem, M.E. Percy, D.F. Andrews, T.P. Kruck, S. Wong, A.J. Dalton, P. Mehta, B. Fedor and A.C. Warren, Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 93 (2000), 58-66.
67. S. Murphy, M.D. Curran, N. McDougall, M.E. Callender, C.J. O'Brien and D. Middleton, High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population-implications for haemochromatosis, Tissue Antigens 52 (1998), 484-488.
68. K. Namekata, M. Imagawa, A. Terashi, S. Ohta, F. Oyama and Y. Ihara, Association of transferrin C2 allele with late-onset Alzheimer's disease, Hum Genet 101 (1997), 126-129.
69. C. Niederau, G. Strohmeyer and W. Stremmel, Epidemiology, clinical spectrum and prognosis of hemochromatosis, Adv Exp Med Biol 356 (1994), 293-302.
70. J.E. Nielsen, L.N. Jensen and K. Krabbe, Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome, J Neurol Neurosurg Psychiatry 59 (1995), 318-321.
71. M. Pandolfo, Iron metabolism and mitochondrial abnormalities in Friedreich ataxia, Blood Cells Mol Dis 29 (2002), 536-547; discussion 548-552.
72. A.C. Pereira, M.A. Cuoco, G.F. Mota, F.F. da Silva, H.F. Freitas, E.A. Bocchi, J.M. Soler, A.J. Mansur and J.E. Krieger, Hemochromatosis gene variants in patients with cardiomyopathy, Am J Cardiol 88 (2001), 388-391.
73. G. Perry, M.A. Smith, C.E. McCann, S.L. Siedlak, P.K. Jones and R.P. Friedland, Cerebrovascular muscle atrophy is a feature of Alzheimer's disease, Brain Res 791 (1998), 63-66.
74. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, J.M. Egan and N.H. Greig, Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron, J Neurosci Res 72 (2003), 603-612.
75. P.D. Phatak, D.H. Ryan, J. Cappuccio, D. Oakes, C. Braggins, K. Provenzano, S. Eberly and R.L. Sham, Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients, Blood Cells Mol Dis 29 (2002), 41-47.
76. D.J. Pinero, J. Hu and J.R. Connor, Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains, Cell Mol Biol (Noisy-le-grand) 46 (2000), 761-776.
77. D.J. Pinero, J. Hu, B.M. Cook, R.C. Jr. Scaduto and J.R. Connor, Interleukin-1beta increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool, Biochim Biophys Acta 1497 (2000), 279-288.
78. J.F. Pulliam, C.D. Jennings, R.J. Kryscio, D.G. Davis, D. Wilson, T.J. Montine, F.A. Schmitt and W.R. Markesbery, Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE, Am J Med Genet 119B (2003), 48-53.
79. S. Ristic, L. Lovrecic, B. Brajenovic-Milic, N. Starcevic-Cizmarevic, S.S. Jazbec, J. Sepcic, M. Kapovic and B. Peterlin, Mutations in the hemochromatosis gene (HFE) and multiple sclerosis, Neurosci Lett 383 (2005), 301-304.
80. S.J. Robb, L.D. Robb-Gaspers, R.C. Jr., Scaduto, A.P. Thomas and J.R. Connor, Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes, J Neurosci Res 55 (1999), 674-686.
81. K.J. Robson, D.J. Lehmann, V.L. Wimhurst, K.J. Livesey, M. Combrinck, A.T. Merryweather-Clarke, D.R. Warden and A.D. Smith, Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease, J Med Genet 41 (2004), 261-265.
82. J.T. Rogers, J.D. Randall, C.M. Cahill, P.S. Eder, X. Huang, H. Gunshin, L. Leiter, J. McPhee, S.S. Sarang, T. Utsuki, N.H. Greig, D.K. Lahiri, R.E. Tanzi, A.I. Bush, T. Giordano and S.R. Gullans, An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript, J Biol Chem 277 (2002), 45518-45528.
83. E. Rossi, M.K. Bulsara, J.K. Olynyk, D.J. Cullen, L. Summerville and L.W. Powell, Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population, Clin Chem 47 (2001), 202-208.
84. C.A. Rottkamp, A.K. Raina, X. Zhu, E. Gaier, A.I. Bush, C.S. Atwood, M. Chevion, G. Perry and M.A. Smith, Redox-active iron mediates amyloid-beta toxicity, Free Radic Biol Med 30 (2001), 447-450.
85. C.N. Roy, A.O. Custodio, J. de Graaf, S. Schneider, I. Akpan, L.K. Montross, M. Sanchez, A. Gaudino, M.W. Hentze, N.C. Andrews and M.U. Muckenthaler, An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice, Nat Genet 36 (2004), 481-485.
86. J.P. Rubio, M. Bahlo, N. Tubridy, J. Stankovich, R. Burfoot, H. Butzkueven, C. Chapman, L. Johnson, M. Marriott, G. Mraz, B. Tait, C. Wilkinson, B. Taylor, T.P. Speed, S.J. Foote and T.J. Kilpatrick, Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis, Hum Genet 114 (2004), 573-580.
87. M. Sampietro, L. Caputo, A. Casatta, M. Meregalli, A. Pellagatti, J. Tagliabue, G. Annoni and C. Vergani, The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease, Neurobiol Aging 22 (2001), 563-568.
88. Sheldon, Hemochromatosis, London: Oxford Univ. Press 1935, 155-159.
89. M. Simon, Y. Pawlotsky, M. Bourel, R. Fauchet and B. Genetet, Idiopathic hemochromatosis associated with HL-A 3 tissular antigen, Nouvelle Press Medicale 4 (1975), 1432.
90. K.J. Thompson, M.G. Fried, Z. Ye, P. Boyer and J.R. Connor, Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei, J Cell Sci 115 (2002), 2165-2177.
91. T. van Groen and I. Kadish, Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology, Brain Res Brain Res Rev 48 (2005), 370-378.
92. G. Vanhoutte, I. Dewachter, P. Borghgraef, F. Van Leuven and A. Van der Linden, Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP V717I transgenic mice, a model for Alzheimer's disease, Magn Reson Med 53 (2005), 607-613.
93. A. Venti, T. Giordano, P. Eder, A.I. Bush, D.K. Lahiri, N.H. Greig and J.T. Rogers, The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron-Responsive Element in the APP-mRNA 5′-Untranslated Region, Ann N Y Acad Sci 1035 (2004), 34-48.
94. X.S. Wang, S. Lee, Z. Simmons, P. Boyer, K. Scott, W. Liu and J. Connor, Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences, J Neurol Sci 227 (2004), 27-33.
95. M. Worwood, HFE Mutations as risk factors in disease, Best Pract Res Clin Haematol 15 (2002), 295-314.
96. J. Yaouanq, A. El Kahloun, M. Chorney, A.M. Jouanolle, V. Mauvieux, M. Perichon, M. Blayau, P. Pontarotti, J.Y. Le Gall and V. David, Familial screening for genetic haemochromatosis by means of DNA markers, J Med Genet 29 (1992), 320-322.
97. Z. Ye and J.R. Connor, Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells, Biochem Biophys Res Commun 264 (1999), 709-713.
98. A.A. Yen, E.P. Simpson, J.S. Henkel, D.R. Beers and S.H. Appel, HFE mutations are not strongly associated with sporadic ALS, Neurology 62 (2004), 1611-1612.
99. P. Zhang, W. Land, S. Lee, J. Juliani, J. Lefman, S.R. Smith, D. Germain, M. Kessel, R. Leapman, T.A. Rouault and S. Subramaniam, Electron tomography of degenerating neurons in mice with abnormal regulation of iron metabolism, J Struct Biol 150 (2005), 144-153.
100. X. Zhang, M. Haaf, B. Todorich, E. Grosstephan, H. Schieremberg, N. Surguladze and J.R. Connor, Cytokine toxicity to oligodendrocyte precursors is mediated by iron, Glia 52 (2005), 199-208.